A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to demonstrate that Super‐Responders (SRe; defined as psoriasis participants who receive on‐label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).
Epistemonikos ID: e6d6865aa8d4faaf20f96b844dfe6636077bf12c
First added on: May 21, 2024